STRUCTURAL EXPLORATION AND PHARMACOPHORIC INVESTIGATION OF PYRAZOLE BASED ANALOGS AS NOVEL HISTONE DEACETYLASE 1 INHIBITOR USING COMBINATORIAL STUDIES

Objective: Histone deacetylase inhibitors (HDACi) have four essential pharmacophores as cap group, connecting unit, a linker moiety and zinc binding group for their anticancer and histone deacetylase (HDAC) inhibition activity. On the basis of this fact, the objective of this research was to evaluate the exact role of pyrazole nucleus as connecting unit and its role in the development of newer HDACi.Methods: Ligand and structure-based computer-aided drug design strategies such as pharmacophore and atom based 3D QSAR modelling, molecular docking and energetic based pharmacophore mapping have been frequently applied to design newer analogs in a precise manner. Herein, we have applied these combinatorial approaches to develop the structure-activity correlation among novel pyrazole-based derivatives.Results: the Pharmacophore-based 3D-QSAR model was developed employing Phase module and e-pharmacophore on compound 1. This 3D-QSAR model provides fruitful information regarding favourable and unfavourable substitution on pyrazole-based analogs for HDAC1 inhibition activity. Molecular docking studies indicated that all the pyrazole derivatives bind with HDAC1 proteins and showed critical hydrophobic interaction with 5ICN and 4BKX HDAC1 proteins.Conclusion: The outcome of the present research work clearly indicated that pyrazole nucleus added an essential hydrophobic feature in cap group and could be employed to design the ligand molecules more accurately

Cobalt Telluride Electrocatalyst for Selective Electroreduction of CO2 to Value-Added Chemicals

Recent emphasis on carbon dioxide utilization has necessitated the exploration of different catalyst compositions other than copper-based systems that can significantly improve the activity and selectivity towards specific CO2 reduction products at low applied potential. In this study, a binary CoTe has been reported as an efficient electrocatalyst for CO2 reduction in aqueous medium under ambient conditions at neutral pH. CoTe showed high Faradaic efficiency and selectivity of 86.83 and 75%, respectively, for acetic acid at very low potential of − 0.25 V vs RHE. More intriguingly, C1 products like formic acid was formed preferentially at slightly higher applied potential achieving high formation rate of 547.24 μmol cm−2 h−1 at − 1.1 V vs RHE. CoTe showed better CO2RR activity when compared with Co3O4, which can be attributed to the enhanced electrochemical activity of the catalytically active transition metal center as well as improved intermediate adsorption on the catalyst surface. While reduced anion electronegativity and improved lattice covalency in tellurides enhance the electrochemical activity of Co, high d-electron density improves the intermediate CO adsorption on the catalyst site leading to CO2 reduction at lower applied potential and high selectivity for C2 products. CoTe also shows stable CO2RR catalytic activity for 50 h and low Tafel slope (50.3 mV dec–1) indicating faster reaction kinetics and robust functionality. Selective formation of value-added C2 products with low energy expense can make these catalysts potentially viable for integration with other CO2 capture technologies thereby, helping to close the carbon loop

Release Analysis of Coal

Washing of fines is more problematic than the washing of coarse coal. One of the perceived barriers in large scale application of flotation in the cleaning of Indian coking coal is the absence of benchmarking. Release analysis is the counterpart in froth flotation to float and sink analysis in the gravity concentration of coal. Thus it provides a benchmark for the coal flotation actually carr-ied out in plants. The present work has been carried out with a LVC coal following the BS 7530 procedure of release analysis. Reagents used include MIBC as the common frother and n-dodecane and a synthetic collector, as the two colle-cting agents. Current published research indicates that with LVC coal only about 20- 30% yield at 18-19% ash cont-ent could be obtained. However, in the present work yields, up to 62% at about the same ash content could be obtained

AYURVEDA AS A CO-THERAPY IN THE MANAGEMENT OF OLIGOASTROCYTOMA: A CASE STUDY

Anaplastic astrocytoma (AA) is a diffusely infiltrating malignant, astrocytic, primary brain tumour with a peak incidence between 40 to 50 years of age is a leading cause of cancer death. Though cancer chemotherapy is highly effective in many cancers, but side-effects of chemotherapy are severe in many patients like myelosuppression, anorexia, weight loss, mucositis, fatigue, nausea, vomiting and diarrhoea. It appears that side effects of chemotherapy are manifestations of aggravated Tridosha as Raktadushti (vitiated blood). Therefore, present case study was undertaken to find effectiveness of Ayurvedic medication as an adjuvant or co-therapy in the management of oligoastrocytoma as well as in minimizing the side effect of chemo-radiotherapy. A female patient of age 40 years with brain cancer (clinically diagnosed case of anaplastic oligoastrocytoma grade 3rd) undergoing oral chemotherapy by irnocam 150 mg, avastin 400mg for 6 cycle and radiotherapy was taken. Patient was given classical Ayurvedic formulation of Rasa sindur 50mg+ Abhrakbhasma 250mg+ Vachachurna 500mg+ Panchamritalauha guggulu 250mg BD with honey, Shatavarighrita 5gm BD with milk, Jyotishmatitaila 5 drops BD with Bataasha and cap SNEC30 (liquid curcumin capsules). After the completion of 6th cycle there were very encouraging results observed with negligible side effects, improvement in all chief complaints, general health condition and quality of life of the patient. Ayurvedic medication appears to have significant effect on reducing side effect of chemo-radiotherapy and improving quality of life in the patient of brain cancer (oligoastrocytoma)

Concept of Parmanuvada and its Utility

Ayurveda is a scientific discipline and it had been developed by the ancient ages based on their great clinical observations and successive testing. For its proper application and understanding various philosophical concept have been taken by our Acharya as they form the fundamental principles of Ayurvedic science. When we go through the subject deeply in Ayurveda science, we find the effect of Bhartiya Darshana on it. According to the Vaisheshika Darshana, all objects of the universe are composed of atoms of earth, water, air and fire. Hence, the vision of the Vaisheshika Darshana about creation is called Atomism or Paramanuvada. The atomic theory of the Vaisheshika explains that part of the world which is non eternal, i.e., subject to origin and destruction in time. The eternal constituents of the universe, namely the four kinds of atoms and five substances of Akas, space, time and soul. So, the atomic theory explains the order of creation and destruction of these non-eternal object. The description of Paramanuvada in Vaisheshika Darshana is mainly for the clarification of the Srishti Utpatti. But the explanation of Acharya Charaka is based on the medicinal point of view. The Samyoga and Viyoga of these Parmanu is mainly due to Vayu, Karma and Swabhava. In this article importance of Paramaanuvada, as given in Vaisheshika Darshana has been made and attempted to search and understanding the subjects where Paramaanuvada is applied and can be applicable in Ayurveda

A contemporary investigation of force transducers: Past and present scenario

In this paper, retrospective investigation of different types of force transducers, used in different applications (metrological, industrial, scientific etc.) for force measurement, has been done. The paper discusses the complete classification of force transducers based on shape, display and applications. Various types of force transducer have been discussed in the paper including symmetrical, unsymmetrical and alteration types. An attempt has been made to provide a comprehensive investigation related to metrological aspects of force transducer

UV Spectrum of 1,3-Dithiolan-2-one in Cyclohexane

1094-109